**Dear editor**

I read with great interest the systematic review of meta-analysis assessing probiotics for the prevention of *Clostridium difficile*-associated diarrhea (CDAD) published in the *International Journal of General Medicine*.[@b1-ijgm-9-333] These authors pooled 26 randomized controlled trials (RCTs) and concluded that *Lactobacilli*, mixtures, and *Saccharomyces* probiotics were effective in preventing CDAD. However, the meta-analysis by Lau and Chamberlain is flawed due to improper classification by the types of probiotics. It is important to recognize that the efficacy of probiotics for various diseases has been shown to be strain specific for each probiotic product, and thus the data should only be pooled for probiotics that are of the identical type.[@b2-ijgm-9-333],[@b3-ijgm-9-333] In their analysis of probiotic subgroups by various species, the authors have inappropriately merged different types of *Lactobacilli* into one subgroup "*Lactobacilli*" and different types of mixtures into one group classified as "Mix". The *Lactobacilli* subgroup actually contains RCTs using six different types of *Lactobacilli*: *Lactobacilli rhamnosus* GG (three RCTs), one mixture of three *Lactobacilli* strains (*Lactobacilli acidophilus* CL1285, *Lactobacilli casei* LBC80R, and *L. rhamnosus* CLR2) (three RCTs), *L. acidophilus* (one RCT), one mixture of three strains of *L. rhamnosus* (E/n, Oxy, and Pen) (one RCT), *L. casei* Shirota (one RCT), and *Lactobacilli plantarum* 299v (one RCT). The Mix subgroup contains RCTs of five different types of strains, and only two trials evaluated the same type of probiotic mixture (*L. acidophilus* and *Bifidobacterium bifidum*). Only the *Saccharomyces* subgroup correctly pooled seven RCTs using the same strain of probiotic (*Saccharomyces boulardii* CNCM I-745). When these subgroups are pooled appropriately, as shown in [Figure 1](#f1-ijgm-9-333){ref-type="fig"}, only three types of probiotics have efficacy for the primary prevention of CDAD: *S. boulardii* (*P*=0.003) and two mixtures (BioK+, a mixture of three *Lactobacilli* strains[@b4-ijgm-9-333] \[*P*\<0.001\] and the mixture of *L. acidophilus* with *B. bifidum* \[*P*=0.002\]). *L. rhamnosus* GG did not significantly prevent CDAD (*P*=0.65), a finding that is not apparent in the meta-analysis presentation of Lau and Chamberlain. No other probiotic strains had a second confirmatory RCT, and hence it is inappropriate to pool these different strains together. Only by appropriately combining and pooling data using the same strain or strains of probiotics can practical clinical guidance be determined as to which specific probiotic strains can be used to prevent CDAD.
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**Dear editor**

We appreciate the editorial comments and suggestions by McFarland included here, as well as the ability to respond to their critique. This author makes several valid points about the type of data, which is clearly needed to better understand the impact of specific probiotics on *Clostridium difficle*-associated diarrhea (CDAD) prevention. The previously published meta-analysis entitled "Probiotics are effective at preventing *Clostridium difficile*-associated diarrhea: a systematic review and meta-analysis" was performed to evaluate the impact of probiotics on CDAD.[@b20-ijgm-9-333] Given existing data, the only means to answer this question via meta-analysis required that all existing data be pooled. That said, we also conducted a subgroup analysis based on the genus of probiotic, to determine which probiotic genus (*Lactobacillus*, *Bifidobacterium*, and *Saccharomyces*) were most beneficial at preventing CDAD. The category "mixture of probiotics" included strains from more than one probiotic genus. As suggested by McFarland in their editorial, additional more detailed subgroup analysis based on unique probiotic species would be ideal; however, given the variation in specific species utilized in published reports, the paucity of published randomized control trials (RCTs) evaluating each species, and the fact that the vast majority of all published RCTs included a combination of different probiotic species, a subgroup analysis by probiotic species was not possible.

As mentioned in the "Discussion" section, there are limitations to our published report, as well as limitations that are inherent to meta-analyses in general. The specific strains, dosages, and duration of probiotic regimen differed widely. Ideally, the best way to determine the optimal probiotic regimen would be to conduct RCTs comparing specific strains and dosages of probiotics. Given the limited availability of such data, the next-best method is the use of a subgroup analysis. The original article demonstrated the effectiveness of probiotics in reducing the risk of CDAD, and a subgroup analysis identified different efficacies based on probiotic genus.[@b20-ijgm-9-333] More recently, McFarland reported that there were efficacy differences based on specific species -- and that *S. boulardii*, BioK+ mixture, a mixture of three *Lactobacilli* strains, and a mixture of *L. acidophilus* plus *B. bifidum* are beneficial at reducing the risk of CDAD, while *L. rhamnosus* GG does not significantly reduce the risk of CDAD.
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